Radioligand therapy (RLT) targeting the prostate-specific membrane antigen (PSMA) is an emerging treatment modality for advanced prostate cancer, but 50% of patients with PSMA-positive tumors experience treatment failure. Here, FOLH1 is linked to prostate cancer.